Xeriant Inc (XERI)

[Smartypants2]

The assumption that XERI would pay so much money and give away so much of the potential revenue from the sale of Retacell-enhanced products WITHOUT REQUIRING ANY ADDITIONAL INPUT OR CONTRIBUTIONS IN PRODUCT DEVELOPMENT from Movychem, beyond the transfer of the basic Retacell IP, is totally absurd and ill-informed!

In fact, had Movychem wished to wash its hands of any additional responsibilities towards the practical application and commercialization of Retacell, such a disclaimer would have been clearly included in their JV Agreement. In addition, it never would have attempted (and subsequently failed) to provide those services, as so indicated in the S1/A.

Movychem may have spent 20 years developing Retacell, but when it came to helping XERIANT produce a commercially viable product around it, they stopped too far from the finish line. XERI would have been crazy to pay them that $2 million under the circumstances!